Crystallizing Hepatitis B Virus Reverse Transcriptase
结晶乙型肝炎病毒反转录酶
基本信息
- 批准号:7033057
- 负责人:
- 金额:$ 23.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-04-01 至 2008-12-31
- 项目状态:已结题
- 来源:
- 关键词:RNA directed DNA polymeraseSDS polyacrylamide gel electrophoresisX ray crystallographyaffinity chromatographycrystallizationhepatitis B virus groupprotein protein interactionprotein purificationprotein structure functionrecombinant proteinsribonucleoproteinsstructural biologytissue /cell culturetranscription factortransfection /expression vectorvirus proteinvirus replication
项目摘要
DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) remains a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. HBV is a member of the hepadnavirus group, double-stranded DNA viruses. It replicates through an RNA intermediate (the pregenomic RNA, or pgRNA) by a novel reverse transcription pathway. To carry out this unusual replication cycle, all hepadnaviruses encode a multi-functional reverse transcriptase (RT). A critical early step in HBV replication is the assembly of a specific ribonucleoprotein (RNP) complex between the viral reverse transcriptase (RT) and a specific RNA signal called Epsilon, located at the 5' end of the pgRNA. Using epsilon RNA as a template, the RT is able to initiate DNA synthesis de novo (without the need of any nucleic acid primers), using itself as a protein primer (the protein priming reaction). The RT-epsilon complex also acts as a packaging signal to initiate assembly of the viral nucleocapsids, leading to the selective incorporation of both the RT and the pgRNA into the locale of reverse transcription. Therefore, RT functions, in particular, its interaction with the Epsilon RNA and its protein priming activity, are critical for HBV assembly and replication and as such, represent excellent targets to develop specific anti-HBV agents. Our recent success in expressing and purifying active, recombinant HBV RT proteins has brought about the exciting possibility that sufficient amounts of RT proteins could now be purified for high-resolution structural studies using X-ray crystallography. Therefore, it is proposed in this exploratory project to apply the technology of X-ray crystallography to study the RT functions. Sufficient amounts of RT proteins, and the RT-epsilon complex will be purified for crystallization, with the long-term objective of obtaining their high-resolution structures. In addition, a novel domain of the RT protein, called TP domain, will be purified and crystallized. To accomplish these goals, the current bacterial expression system will be scaled up and if necessary, eukaryotic expression systems will be adopted. Together with other biochemical studies, the high-resolution structure studies proposed here will greatly enhance our understanding of the mechanisms of RT-epsilon interaction and protein priming. Furthermore, the anticipated results from biochemical and structural studies will facilitate structure-based rational design of novel anti-HBV agents targeting at RT-epsilon interaction and protein priming, which, in turn, will help to prevent the development of HBV-induced liver cancer and other fatal diseases.
描述(由申请人提供):B肝炎病毒(HBV)仍然是慢性肝炎、肝硬化和肝细胞癌的主要原因。HBV是嗜肝DNA病毒组(双链DNA病毒)的成员。它通过一种新的逆转录途径通过RNA中间体(前基因组RNA或pgRNA)进行复制。为了进行这种不寻常的复制循环,所有嗜肝DNA病毒编码一种多功能逆转录酶(RT)。HBV复制的关键早期步骤是在病毒逆转录酶(RT)和位于pgRNA 5'端的称为EpcRNA的特异性RNA信号之间组装特异性核糖核蛋白(RNP)复合物。使用RNA作为模板,RT能够启动DNA从头合成(不需要任何核酸引物),使用自身作为蛋白质引物(蛋白质引发反应)。RT-PCR复合物还充当包装信号以启动病毒核衣壳的组装,导致RT和pgRNA两者选择性地掺入逆转录的区域中。因此,RT功能,特别是其与EpiRNA的相互作用及其蛋白质引发活性,对于HBV组装和复制至关重要,因此代表了开发特异性抗HBV药物的极好靶点。我们最近在表达和纯化活性的重组HBV RT蛋白方面的成功带来了令人兴奋的可能性,即现在可以纯化足够量的RT蛋白用于使用X射线晶体学的高分辨率结构研究。因此,本课题拟应用X射线晶体学技术研究RT功能。 将纯化足够量的RT蛋白和RT-PCR复合物用于结晶,长期目标是获得其高分辨率结构。此外,RT蛋白的一个新结构域,称为TP结构域,将被纯化和结晶。为了实现这些目标,将扩大目前的细菌表达系统,如果需要,将采用真核表达系统。与其他生物化学研究一起,这里提出的高分辨率结构研究将大大提高我们对RT-PCR相互作用和蛋白质启动机制的理解。此外,生化和结构研究的预期结果将有助于基于结构的合理设计新的抗HBV药物,靶向RT-PCR相互作用和蛋白质引发,这反过来将有助于预防HBV诱导的肝癌和其他致命疾病的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hwai-Chen Guo其他文献
Hwai-Chen Guo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hwai-Chen Guo', 18)}}的其他基金
Structural and Bioinformatics Analyses of M1 Aminopeptidases
M1 氨基肽酶的结构和生物信息学分析
- 批准号:
10437967 - 财政年份:2018
- 资助金额:
$ 23.66万 - 项目类别:
Towards Structural Studies of Aminopeptidases in Antigen Processing
抗原加工中氨基肽酶的结构研究
- 批准号:
7877060 - 财政年份:2009
- 资助金额:
$ 23.66万 - 项目类别:
Towards Structural Studies of Aminopeptidases in Antigen Processing
抗原加工中氨基肽酶的结构研究
- 批准号:
8236091 - 财政年份:2009
- 资助金额:
$ 23.66万 - 项目类别:
Structure-Based Design of Small Molecules for Aspartylglucosaminuria
基于结构的天冬氨葡萄糖胺尿小分子设计
- 批准号:
8239512 - 财政年份:2008
- 资助金额:
$ 23.66万 - 项目类别:
Structural studies on an aminopeptidase inside the endoplasmic reticulum
内质网内氨肽酶的结构研究
- 批准号:
7643263 - 财政年份:2008
- 资助金额:
$ 23.66万 - 项目类别:
Structure-Based Design of Small Molecules for Aspartylglucosaminuria
基于结构的天冬氨葡萄糖胺尿小分子设计
- 批准号:
8012809 - 财政年份:2008
- 资助金额:
$ 23.66万 - 项目类别:
Structural studies on an aminopeptidase inside the endoplasmic reticulum
内质网内氨肽酶的结构研究
- 批准号:
7530620 - 财政年份:2008
- 资助金额:
$ 23.66万 - 项目类别:
Structure-Based Design of Small Molecules for Aspartylglucosaminuria
基于结构的天冬氨葡萄糖胺尿小分子设计
- 批准号:
7341477 - 财政年份:2008
- 资助金额:
$ 23.66万 - 项目类别:
Structure-Based Design of Small Molecules for Aspartylglucosaminuria
基于结构的天冬氨葡萄糖胺尿小分子设计
- 批准号:
7554622 - 财政年份:2008
- 资助金额:
$ 23.66万 - 项目类别:
Crystallizing Hepatitis B Virus Reverse Transcriptase
结晶乙型肝炎病毒反转录酶
- 批准号:
6851919 - 财政年份:2005
- 资助金额:
$ 23.66万 - 项目类别: